DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the ...

DUBLIN, July 09, 2024--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that it has received regulatory approvals in the European Union, the United Kingdom and Australia for full-body MR ...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ...

Mechanical chronic low back pain results from an injury or stress on the tissues surrounding the spine, including soft tissues, muscles, bones, and joints. Often, this type of pain is due to impaired ...

ReActiv8 is now supported by the most complete and robust set of clinical evidence of any neuromodulation therapy for axial back pain globally. The study included 203 patients, with 99 randomized into ...

Mainstay Medical Holdings plc, a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical ...

Anyone living with chronic low back pain frequently has one wish on their mind: “Fix. My. Lower. Back.” Now, a new clinically proven restorative treatment option called ReActiv8 could make a ...

Data continue to show compelling efficacy and safety, including improvement on all key measures of pain and disability, as compared to the one-year and two-year study results Mainstay Medical Holdings ...

New real-world evidence further supports the efficacy and use of ReActiv8 Restorative Neurostimulation for the treatment of intractable Chronic Low Back Pain Mainstay Medical Holdings plc today ...